Adenoviral 15-lipoxygenase-1 gene transfer inhibits hypoxia-induced proliferation of retinal microvascular endothelial cells in vitro

International Journal of Ophthalmology

Volumn 5, Issue 5, 2012, Pages 562-569

  Yan, Ying ^a,b   He, Tao ^a   Shen, Ying ^a   Chen, Xiao ^b   Diao, Bo ^b   Li, Zhi ^c   Liu, Qing ^b   Xing, Yi Qiao ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^c Xiangyang Center Hospital   (China)

Author keywords

15 Lipoxygenase 1; Hypoxia; Retinal neovascularization; Retinalmicrovascular endothelial cells

Indexed keywords

EID: 84879627173     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2012.05.04     Document Type: Article

References (34)

1. Gariano RF, Gardner TW Retinal angiogenesis in development and disease. Nature. 2005;438(7070):960-966.
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H., Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N., King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487.
3. Wang X, Wang G, Wang Y. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2009;148(6):883-889.
4. Adamis AP, Shima DT The role of vascular endothelial growth factor in ocular health and disease. 2005;25(2):111-118.
5. Witmer AN, Vrensen G, Van Noorden CJ, Schlingemann RO Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22(1):1-29.
6. Xia XB, Xiong SQ, Song WT, Luo J., Wang YK, Zhou RR Inhibition of retinal neovascularization by sirna targeting vegf165. Mol Vis. 2008;14:1965-1973.
7. Zhang SX, Wang JJ, Gao G, Parke K., Ma JX Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF, VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol. 2006;37(1):1-12.
8. Aiello LP, Pierce EA, Foley ED, Takagi H., Chen H, Riddle L, Ferrara N., King GL, Smith LE Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble vegf-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92(23):10457- 10461.
9. Kuhn H, Chaitidis P, Roffeis J., Walther M. Arachidonic acid metabolites in the cardiovascular system: The role of lipoxygenase isoforms in atherogenesis with particular emphasis on vascular remodeling. J Cardiovasc Pharmacol. 2007;50(6):609-620.
10. Brash AR. Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999;274(34):23679-23682.
11. Kuhn H, Thiele BJ The diversity of the lipoxygenase family: Many sequence data but little information on biological significance1. FEBS Lett. 1999;449(1):7-11.
12. Brash AR, Boeglin WE, Chang MS Discovery of a second 15s-lipoxygenase in humans. Proc Natl Acad Sci U S A. 1997;94(12):6148-6152.
13. Chanez P, Bonnans C, Chavis C., Vachier I. 15-lipoxygenase: A janus enzyme? Am J Respir Cell Mol Biol. 2002;27(6):655-658.
14. Kuhn H, Walther M, Kuban RJ. Mammalian arachidonate 15-lipoxygenases: Structure, function, and biological implications. Prostaglandins Other Lipid Mediat. 2002;68-69:263-290.
15. Funk CD. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta. 1996;1304(1):65-84.
16. Shappell SB, Boeglin WE, Olson SJ, Kasper S., Brash AR 15-lipoxygenase-2 (15-lox-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol. 1999;155(1):235-245.
17. Fürstenberger G., Krieg P, Müller-Decker K, Habenicht AJ. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer. 2006;119(10):2247-2254.
18. Kuhn H, Römisch I, Belkner J. The role of lipoxygenase isoforms in atherogenesis. Mol Nutr Food Res. 2005;49(11):1014-1029.
19. Cyrus T, Witztum JL, Rader DJ, Tangirala R., Fazio S, Linton MRF, Funk CD Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo e-deficient mice. J Clin Invest. 1999;103(11):1597-1604.
20. Shen J, Herderick E, Cornhill JF, Zsigmond E., Kim HS, Kühn H, Guevara NV, Chan L. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest. 1996;98(10):2201-2208.
21. Harats D, Ben-Shushan D, Cohen H., Gonen A, Barshack I, Goldberg I., Greenberger S, Hodish I, Harari A., Varda-Bloom N, Levanon K, Grossman E, Chaitidis P, Kühn H, Shaish A. Inhibition of carcinogenesis in transgenic mouse models over-expressing 15-lipoxygenase in the vascular wall under the control of murine preproendothelin-1 promoter. Cancer Lett. 2005;229(1):127-134.
22. Kelavkar UP, Nixon JB, Cohen C, Dillehay D., Eling TE, Badr KF Overexpression of 15-lipoxygenase-1 in pc-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis. 2001;22(11):1765-1773.
23. Yang M, Zhou H. Grass carp transforming growth factor-beta 1 (TGF-beta 1): Molecular cloning, tissue distribution and immunobiological activity in teleost peripheral blood lymphocytes. Mol Immunol. 2008;45(6):1792-1798.
24. Godfrey TE, Kim SH, Chavira M, Ruff DW, Warren RS, Gray JW, Jensen RH Quantitative mrna expression analysis from formalin-fixed, paraffin-embedded tissues using 5-nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn. 2000;2(2):84-91.
25. Livak KJ, Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
26. Bradley J, Ju M, Robinson GS Combination therapy for the treatment of ocular neovascularization. Angiogenesis. 2007;10(1):141-148.
27. Spaide RF, Fisher YL Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26(3):275-278.
28. Oshima Y, Sakaguchi H, Gomi F., Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142(1):155-158.
29. Hernández C., Simó R. Strategies for blocking angiogenesis in diabetic retinopathy: From basic science to clinical practice. Expert Opin Investig Drugs. 2007;16(8):1206-1226.
30. Viita H, Markkanen J, Eriksson E., Nurminen M, Kinnunen K, Babu M., Heikura T, Turpeinen S, Laidinen S., Takalo T, Ylä-Herttuala S. 15-lipoxygenase-1 prevents vascular endothelial growth factor A and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression. Circ Res. 2008;102:177-184.
31. Nagy L, Tontonoz P, Alvarez JG, Chen H., Evans RM Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93(2):229-240.
32. Sassa Y, Hata Y, Aiello LP, Taniguchi Y., Kohno K, Ishibashi T. Bifunctional properties of peroxisome proliferator-activated receptor gammal in KDR gene regulation mediated via interaction with both Sp1 and Sp3. Diabetes. 2004;53(5):1222-1229.
33. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
34. Subramanian ML, Abedi G, Ness S., Ahmed E, Fenberg M, Daly MK, Houranieh A., Feinberg EB Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye. 2010;24(11):1708-1715.